Bedaquiline (fuMarate)

Bedaquiline (fuMarate)
  • CAS No.:845533-86-0
Other grades of this product :
Bedaquiline (fuMarate) Basic information
Product Name:Bedaquiline (fuMarate)
Synonyms:(1R,2S)-1-(6-bromo-2-methoxyquinolin-3-yl)-4-(dimethylamino)-2-(naphthalen-1-yl)-1-phenylbutan-2-ol fumarate;(1R,2S)-1-(6-Bromo-2-methoxy-3-quinolinyl)-4-(dimethylamino)-2-(1-naphthyl)-1-phenyl-2-butanol (2E)-2-butenedioate (1:1);Bedaquiline Fumarate salt;Bedaquiline (fuMarate);R 403323;(1R,2S)-1-(6-broMo-2-Methoxyquinolin-3-yl)-4-(diMethylaMino)-2-naphthalen-1-yl-1-phenylbutan-2-ol,(E)-but-2-enedioic acid;TMC-207;TMC207;TMC 207;(1R,2S)-1-(6-bromo-2-methoxy-3-quinolinyl)-4-(dimethylamino)-2-(1-naphthalenyl)-1-phenyl-2-butanol
CAS:845533-86-0
MF:C36H35BrN2O6
MW:671.59
EINECS:
Product Categories:
Mol File:845533-86-0.mol
Bedaquiline (fuMarate) Chemical Properties
storage temp. Inert atmosphere,Room Temperature
Safety Information
MSDS Information
Bedaquiline (fuMarate) Usage And Synthesis
DefinitionChEBI: A fumarate salt prepared from equimolar amounts of bedaquiline and fumaric acid. It is used in combination therapy for the treatment of pulmonary multi-drug resistant tuberculosis by inhibition of ATP synthase, an enzyme essential for the replication of th mycobacteria.
Clinical Use

Bedaquiline fumarate is a diarylquinone drug developed by Janssen Pharmaceutical which is marketed under the trade name Sirturo ®. The drug, which was approved in 2012 for the treatment of multidrug-resistant tuberculosis (MDR-TB), was developed in partnership with Johnson & Johnson and represents the first new tuberculosis therapy approved in over four decades. Bedaquiline is the first member of a new class of diarylquinone compounds whose mechanism of action inhibits Mycobaterium tuberculosis ATP synthase which deprives bacterium of energy.

SynthesisOf the relatively few synthetic approaches to bedaquiline (or its fumarate salt) that have been reported, the most likely process-scale route is that described by Porstmann and co-workers from Janssen Pharmaceutical, and this route is outlined in the scheme. The synthesis was initiated by first freebasing commercially available dimethylaminoketone 31 with sodium hydroxide to provide naphthylone 32 in nearly quantitative yield. Subjection of commercially available quinoline 33 to LDA removed the benzyllic proton within this system and subsequent trap with naphthylone 32 gave rise to a mixture of diastereomers whereby the major diastereomer obtained from this reaction corresponded to the bedaquiline geometry. The minor diastereomer was resolved through multiple recrystallizations and seeding techniques. This racemate of the major diastereomer subsequently underwent a chiral resolution upon treatment with BINAP derivative 34 in refluxing DMSO and then upon cooling and subjection to aqueous base in warm toluene furnished bedaquiline 35 bearing the requisite (R,S)- configuration of the two vicinal chiral centers corresponding to that of the drug. The overall yield of the conversion of 33 to enantiopure 35 was 39%. Aminoquinolinol 35 was then prepared as the corresponding fumarate salt upon treatment with fumaric acid in the presence of isopropanol, and this salt formation delivered bedaquiline fumarate (VI) in 82% yield.
Drug interactionsPotentially hazardous interactions with other drugs Antibacterials: concentration possibly increased by ciprofloxacin, clarithromycin and erythromycin - avoid concomitant use if for more than 14 days; avoid with moxifloxacin; concentration possibly reduced by rifampicin - avoid; possibly increased risk of ventricular arrhythmias with clofazimine. Antiepileptics: concentration possibly reduced by carbamazepine, fosphenytoin and phenytoin - avoid. Antivirals: AUC increased by ritonavir, use with caution, avoid in combination with lopinavir.
MetabolismBedaquiline is metabolised mainly by the hepatic CYP3A4 isoenzyme to the N-monodesmethyl metabolite (M2), which is 4-6 times less active than the parent compound. Bedaquiline is excreted mainly in the faeces.
Bedaquiline (fuMarate) Preparation Products And Raw materials
Raw materialsTMC-207-->Hydrocinnamoyl chloride-->N-(4-bromophenyl)-3-phenylpropanamide-->3-benzyl-6-bromo-2-chloroquinoline-->3-Phenylpropionic acid
Preparation Products3-benzyl-6-bromo-2-methoxyquinoline

Welcome!

Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.

  • NO. 18 ,Wujiang Road, Wulidian Street, Jiangbei District, Chongqing
  • +86-23-6139-8061 +86-13650506873
  • danny@chemdad.com sales@chemdad.com
  • www.chemdad.com
  • WhatsApp +86-13650506873

Name

phone

company

email

message

Payment methods
Google translate: 日本语日本语 한국어한국어 FrançaisFrançais DeutschDeutsch EspañaEspaña TürkiyeTürkiye